がん治療薬の世界市場:企業動向、治療、研究開発、市場予測

visiongainが発行した調査報告書(VGAIN5081912)
◆英語タイトル:World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025
◆商品コード:VGAIN5081912
◆発行会社(リサーチ会社):visiongain
◆発行日:2015年7月
◆ページ数:273
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Sigle UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、がん治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・がん治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・主要な抗癌剤
・地域別市場分析、市場規模予測
・がん治療の研究開発パイプライン
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Cancer Treatments – Your New Guide to that Market, its R&D and Sales Potentials
Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2015, helping you stay ahead. There you discover financial data, R&D trends, opportunities, interviews and revenue forecasts.

In our analysis you see forecasted sales to 2025 at overall world market, submarket, product and national level. You assess emerging trends, technologies and branded therapies. With our study, benefit your research, analysis, decisions, presentations and influence.

Events shaping that crucial pharma industry – cancer remains a top priority for healthcare
Discover in our work what the future holds for cancer medicines. Those treatments become ever more important to pharmaceutical companies. Discover why, seeing what shapes that industry. Explore prospects from 2015 for that technology and business.

That way you assess how patients, treatment providers and drug producers stand to benefit from 2015 to 2025. Our study predicts high, rising spending on cancer-treating products. Stay ahead, then, in knowledge to benefit your work.

Please read on now to examine the anti-cancer drugs industry. Also see, below, how high that market’s future revenues could go.

Forecasts from 2015 and other analyses show you therapies’ sales potentials
Is finding data for cancer treatment a challenge? Reduce time spent getting information. Our work shows the most promising and lucrative parts of applied oncology.

Besides revenue forecasting to 2025, our study reveals historical data, growth rates and market shares. You assess quantitative and qualitative analyses, commercial news, outlooks and developments (R&D). In addition, you gain 122 tables, 137 charts and two interviews.

Avoid missing out. The purpose of our analysis is to help you stay ahead in knowledge and benefit your authority on the potential of cancer-treating drugs.

Many opportunities remain for those treatments. Now see how you can benefit your research, analyses and decisions on those medicines, including biological drugs (biologics).

The following sections show how our new investigation helps your work. Discover there how you could benefit your reputation for technological and commercial insight.

Outlooks for the world cancer drugs market and segments – what sales are possible?
Along with prediction of overall world market value to 2025, our report shows you individual revenue forecasting of four therapeutic submarkets at world level:
• Immunotherapy
• Chemotherapy
• Targeted treatments
• Hormone-based therapy.

Our study also discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. You assess leading brands too.

Forecasts for 25 leading drugs and 15 emerging medicines – discover selling potentials
How will leading drugs perform to 2025 at world level? Our study predicts individual revenues of the top 25 anti-cancer agents from 2015, including these products:
• Avastin
• Herceptin
• Rituxan/MabThera
• Gleevec/Glivec
• Revlimid
• Alimta
• Velcade
• Erbitux.

You also discover individual selling potentials of 15 emerging therapies, recently approved, including these agents:
• Farydak
• Ibrance
• Lenvima
• Opdivo
• Unituxin
• Beleodaq
• Cyramza
• Imbruvica.

There, in our analyses, you see how high sales can go, to 2025, finding drugs and years with highest predicted growth and revenues. You examine what’s happening, understanding trends, competition, challenges and opportunities. That information helps you compete.

Our new survey also shows geographical revenue predictions, a breakdown of our overall world market forecast.

Leading national markets – where can highest revenues and growth occur?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2015. Our study shows you the most promising countries for revenues and sales growth.

There you gain individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
• Brazil, Russia, India and China (BRIC nations).

Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2015 to 2025 will change medical prescribing and the commercial landscape.

Discover, too, where R&D in oncology heads.

Research and development – assess innovation, trends and possibilities
What’s happening in oncological R&D? Our study reveals and explains trends for treating cancers. That way you explore drug development in these fields of oncology, by cancer type:
• Breast
• Prostate
• Lung
• Intestinal
• Cervix
• Stomach
• Liver.

Our work also discusses products in development for these cancers, including progress in clinical trials:
• Ovary
• Bladder
• Kidney
• Pancreas
• Non-Hodgkin’s lymphoma
• Leukaemia.

R&D in oncology holds strength, variety and promise. You assess innovations for treating those diseases, hearing about developments and finding their significance. Our study shows you what’s possible to benefit patients, healthcare providers and pharmaceutical companies.

For large firms and specialty pharma there exist many opportunities. Our study explains, discussing issues to help your work. Examine changes shaping that market from 2015.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents

3. The World Anti-Cancer Drugs Market, 2015-2025
3.1 Global Anti-Cancer Drugs Market Forecast, 2015-2025
3.2 The Domination of Immunotherapies in 2014
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2015-2025 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2015-2025
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2015-2025 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2015-2025

4. Leading National Markets, 2015-2025
4.1 Anti-Cancer Drugs – Leading Markets, 2014
4.2 The US Anti-Cancer Drugs Market, 2015-2025 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2014
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Effect of Regulations on the US Market
4.3 The Japanese Anti-Cancer Drugs Market, 2015-2025 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2015-2025 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2015-2025 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2015-2025 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2015-2025 – Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2015-2025 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2015-2025 – Can it Reach its Potential?

5. The Top 25 Anti-Cancer Drugs: Revenue Forecasts, 2015-2025
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2011-2014 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2011-2014 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2011-2014 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2011-2014
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2011-2014 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2011-2014
5.6.2 Alimta Revenue Forecast – Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2011-2014
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2011-2014
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co.) – The Rise of Prevention
5.9.1 Gardasil Revenue, 2011-2014
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2011-2014 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2011-2014 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2011-2014 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2011-2014 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2011-2014
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving Up
5.15.1 Tasigna Revenue, 2011-2014
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16. Sutent (Pfizer)
5.16.1 Sutent Revenue, 2011-2014
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2011-2014 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2011-2014 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2011-2014
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2014
5.20.2 Yervoy Revenue Forecast – Will Sales Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2011-2014
5.21.2 Vidaza Revenue Forecast – Generic Impact?
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2011-2014
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2011-2014
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2011-2014
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2011-2014
5.25.2 Abraxane Revenue Forecast

6. Drugs Approved in 2014-2015: Potential Future Blockbusters
6.1 Approved Treatments in 2015
6.1.1 Farydak (panobinostat/Novartis)
6.1.2 Ibrance (palbociclib/Pfizer)
6.1.3 Lenvima (lenvatinib mesylate/Eisai)
6.1.4 Opdivo (nivolumab/Bristol-Myers Squibb)
6.1.5 Unituxin (dinutuximab/United Therapeutics)
6.2 Approved Treatments in 2014
6.2.1 Beleodaq (belinostat/Spectrum Pharmaceuticals)
6.2.2 Blincyto (blinatumomab/Amgen)
6.2.3 Cyramza (ramucirumab/Eli Lilly): A Breakthrough for Gastric Cancer?
6.2.4 Imbruvica (ibrutinib/Pharmacyclics)
6.2.5 Keytruda (pembrolizumab/Merck)
6.2.6 Lynparza (olaparib/AstraZeneca)
6.2.7 Zydelig (idelalisib/Gilead)
6.2.8 Zykadia (ceritinib/Novartis) – The Rise of Kinase Inhibitors
6.2.9 Tafinlar (Novartis) – A Partner for Mekinist
6.2.10 Kadycla (Roche) – A Future Star

7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – A Pressing Need to Diversify?
7.4.1 Celgene’s Oncology R&D Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing Up the Ladder
7.6.1 Oncology R&D Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck &Co. – Prominent in Vaccines
7.8.1 Oncology R&D Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
7.9 Johnson & Johnson
7.9.1 Oncology J&J Pipeline – A Focus on Prostate Cancer Drugs

8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Veliparib (Abbvie)
8.1.3 NeuVax (Galena Biopharma)
8.1.4 Entinostat (Syndax)
8.2 Prostate Cancer Drugs under Development
8.2.1 ODM-201 (Orion) – Jointly Developed with Bayer
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs under Development
8.3.1 RG7446 (Roche)
8.3.2 Nivolumab (Bristol-Myers Squibb)
8.3.3 MEDI4736 (AstraZeneca)
8.3.4 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 HA-Irinotecan (Alchemia)
8.5 Cervical Cancer Drugs under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.9 Bladder Cancer Drugs under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs under Development
8.12.1 IMA901 (Immatics)
8.12.2 AGS-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)

9. Qualitative Analysis of the Anti-Cancer Drug Market 2015-2025
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment

10. Research Interviews from Our Survey
10.1 Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
10.1.1 D3 Enables Point-of-care and Real Time Testing of Tumours
10.1.2 The Use of D3 to Detect Cancer
10.1.3 D3 – Speed, Ease of Use, Low Cost and Accurate
10.1.4 D3 – Possibility of Detecting Various Types of Cancer
10.1.5 Further Development and Refinement
10.2 Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.
10.2.1 PACE CII – Meeting the Needs of a Diverse Range of Stakeholders
10.2.2 PACE CII – Main Components
10.2.3 PACE CII – a Flexible Framework for Objective Assessments of Progress
10.2.4 Value of Cancer Treatments – Dynamic and Complex
10.2.5 Multiple Stakeholders – Shared Perspectives on Treatment Goals?
10.2.6 Free Access to Database and Tool

11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks

List of Tables
Table 1.1 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2014-2019
Table 1.2 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2019-2025
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2014
Table 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2013-2014
Table 3.3 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2014, 2019 and 2025
Table 3.4 Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2014, 2019, 2025
Table 4.2 Leading National Anti-Cancer Drugs Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025
Table 4.3 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2014
Table 5.2 Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025
Table 5.3 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025
Table 5.4 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
Table 5.6 Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.7 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.8 Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.9 Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.10 Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.11 Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.12 Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.13 Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.14 Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.15 Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.16 Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.17 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.18 Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.19 Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.20 Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.21 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.22 Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.23 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.24 Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.25 Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.26 Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.27 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.28 Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.29 Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.30 Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.31 Afinitor Revenue Forecast ($bn), Annual Growth(%) and CAGR (%), 2015-2025
Table 5.32 Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.33 Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.34 Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.35 Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.36 Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.37 Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.38 Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.39 Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.40 Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.41 Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.42 Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.43 Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.44 Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.45 Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.46 Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.47 Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.48 Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.49 Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.50 Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.51 Temodar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.52 Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.53 Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.54 Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
Table 5.55 Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.1 Farydak: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.2 Ibrance: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.3 Lenvima: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.4 Opdivo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.5 Unituxin: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.6 Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.7 Blincyto: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.8 Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.9 Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.10 Keytruda: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.11 Lynparza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.12 Zydelig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.13 Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.14 Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 6.15 Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 7.1 Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2013-2014
Table 7.2 Roche – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.3 Roche’s Anti-Cancer Drug Development Pipeline, 2014
Table 7.4 Novartis – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.5 Novartis’ Anti-Cancer Drug Pipeline, 2014
Table 7.6 Celgene – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.7 Celgene’s Anti-Cancer Drug Pipeline, 2014
Table 7.8 Eli Lilly – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.9 Eli Lilly’s Anti-Cancer Drug Pipeline, 2014
Table 7.10 AstraZeneca – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.11 AstraZeneca’s Anti-Cancer Drug Pipeline, 2014
Table 7.12 Bristol-Myers Squibb – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.13 Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2014
Table 7.14 Merck – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.15 Merck’s Anti-Cancer Drug Pipeline, 2014
Table 7.16 J&J – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.17 J&J’s Anti-Cancer Drug Pipeline, 2014
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
Table 8.2 Breast Cancer Drugs under Development, 2014
Table 8.3 Prostate Cancer Drugs under Development, 2014
Table 8.4 Lung Cancer Drugs under Development, 2014
Table 8.5 Colorectal Cancer Drugs under Development, 2014
Table 8.6 Cervical Cancer Drugs under Development, 2014
Table 8.7 Stomach Cancer Drugs under Development, 2014
Table 8.8 Liver Cancer Drugs under Development, 2014
Table 8.9 Ovarian Cancer Drugs under Development, 2014
Table 8.10 Bladder Cancer Drugs under Development, 2014
Table 8.11 Non-Hodgkin’s Lymphoma Drugs under Development, 2014
Table 8.12 Leukaemia Drugs under Development, 2014
Table 8.13 Kidney Cancer Drugs under Development, 2014
Table 8.14 Pancreatic Cancer Drugs under Development, 2014
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2015
Table 9.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2015

List of Figures
Figure 1.1 Anti-Cancer Market Segmentation, 2015
Figure 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Global Anti-Cancer Drugs Market: Drivers and Restraints, 2015-2025
Figure 3.3 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2014
Figure 3.4 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2019
Figure 3.5 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2025
Figure 3.6 Global Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Immunotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.8 Global Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.9 Chemotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.10 Global Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.11 Targeted Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.12 Global Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.13 Hormone Therapy Market: Drivers and Restraints, 2015-2025
Figure 4.1 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 4.2 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 4.3 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2014
Figure 4.4 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2019
Figure 4.5 The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2025
Figure 4.6 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 4.7 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 4.8 The EU5 Anti-Cancer Drugs Markets: Revenue Forecast ($bn), 2015-2025
Figure 4.9 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2014
Figure 4.10 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2019
Figure 4.11 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2025
Figure 4.12 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2014
Figure 4.13 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2019
Figure 4.14 BRIC Countries Anti-Cancer Drugs Market Shares (%), 2025
Figure 4.15 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.16 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.17 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 4.18 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
Figure 5.1 Top 10 Anti-Cancer Drugs: Market Share (%), 2014
Figure 5.2 Top 10 Anti-Cancer Drugs: Market Share (%), 2019
Figure 5.3 Top 10 Anti-Cancer Drugs: Market Share (%), 2025
Figure 5.4 Avastin Revenue ($bn), 2011-2014
Figure 5.5 Avastin Revenue Forecast ($bn), 2015-2025
Figure 5.6 Avastin: Drivers and Restraints, 2015-2025
Figure 5.7 Herceptin Revenue ($bn), 2011-2014
Figure 5.8 Herceptin Revenue Forecast ($bn), 2015-2025
Figure 5.9 Herceptin: Drivers and Restraints, 2015-2025
Figure 5.10 Rituxan/MabThera Revenue ($bn), 2011-2014
Figure 5.11 Rituxan/MabThera Revenue Forecast ($bn), 2015-2025
Figure 5.12 Rituxan/MabThera: Drivers and Restraints, 2015-2025
Figure 5.13 Glivec Revenue ($bn), 2011-2014
Figure 5.14 Glivec Revenue Forecast ($bn), 2015-2025
Figure 5.15 Glivec: Drivers and Restraints, 2015-2025
Figure 5.16 Revlimid Revenue ($bn), 2011-2014
Figure 5.17 Revlimid Revenue Forecast ($bn), 2015-2025
Figure 5.18 Revlimid: Drivers and Restraints, 2015-2025
Figure 5.19 Alimta Revenue ($bn), 2011-2014
Figure 5.20 Alimta Revenue Forecast ($bn), 2015-2025
Figure 5.21 Alimta: Drivers and Restraints, 2015-2025
Figure 5.22 Velcade Revenue ($bn), 2011-2014
Figure 5.23 Velcade Revenue Forecast ($bn), 2015-2025
Figure 5.24 Velcade: Drivers and Restraints, 2015-2025
Figure 5.25 Erbitux Revenue ($bn), 2011-2014
Figure 5.26 Erbitux Revenue Forecast ($bn), 2015-2025
Figure 5.27 Erbitux: Drivers and Restraints, 2015-2025
Figure 5.28 Gardasil Revenue ($bn), 2011-2014
Figure 5.29 Gardasil Revenue Forecast ($bn), 2015-2025
Figure 5.30 Gardasil: Drivers and Restraints, 2015-2025
Figure 5.31 Zytiga Revenue ($bn), 2011-2014
Figure 5.32 Zytiga Revenue Forecast ($bn), 2015-2025
Figure 5.33 Zytiga: Drivers and Restraints, 2015-2025
Figure 5.34 Xeloda Revenue ($bn), 2011-2014
Figure 5.35 Xeloda Revenue Forecast ($bn), 2015-2025
Figure 5.36 Xeloda: Drivers and Restraints, 2015-2025
Figure 5.37 Tarceva Revenue ($bn), 2011-2014
Figure 5.38 Tarceva: Revenue Forecast ($bn), 2015-2025
Figure 5.39 Tarceva: Drivers and Restraints, 2015-2025
Figure 5.40 Afinitor Revenue ($bn), 2011-2014
Figure 5.41 Afinitor Revenue Forecast ($bn), 2015-2025
Figure 5.42 Afinitor: Drivers and Restraints, 2015-2025
Figure 5.43 Sprycel Revenue ($bn), 2011-2014
Figure 5.44 Sprycel Revenue Forecast ($bn), 2015-2025
Figure 5.45 Sprycel: Drivers and Restraints, 2015-2025
Figure 5.46 Tasigna Revenue ($bn), 2011-2014
Figure 5.47 Tasigna Revenue Forecast ($bn), 2015-2025
Figure 5.48 Tasigna: Drivers and Restraints, 2015-2025
Figure 5.49 Sutent Revenue ($bn), 2011-2014
Figure 5.50 Sutent: Revenue Forecast ($bn), 2015-2025
Figure 5.51 Sutent: Drivers and Restraints, 2015-2025
Figure 5.52 Nexavar Revenue ($bn), 2011-2014
Figure 5.53 Nexavar: Revenue Forecast ($bn), 2015-2025
Figure 5.54 Nexavar: Drivers and Restraints, 2015-2025
Figure 5.55 Xgeva Revenue ($bn), 2011-2014
Figure 5.56 Xgeva Revenue Forecast ($bn), 2015-2025
Figure 5.57 Xgeva: Drivers and Restraints, 2015-2025
Figure 5.58 Zoladex Revenue ($bn), 2011-2014
Figure 5.59 Zoladex: Revenue Forecast ($bn), 2015-2025
Figure 5.60 Zoladex: Drivers and Restraints, 2015-2025
Figure 5.61 Yervoy Revenue ($bn), 2011-2014
Figure 5.62 Yervoy Revenue Forecast ($bn), 2015-2025
Figure 5.63 Yervoy: Drivers and Restraints, 2015-2025
Figure 5.64 Vidaza Revenue ($bn), 2011-2014
Figure 5.65 Vidaza: Revenue Forecast ($bn), 2015-2025
Figure 5.66 Vidaza: Drivers and Restraints, 2015-2025
Figure 5.67 Treanda Revenue ($bn), 2011-2014
Figure 5.68 Treanda Revenue Forecast ($bn), 2015-2025
Figure 5.69 Treanda: Drivers and Restraints, 2015-2025
Figure 5.70 Temodar Revenue ($bn), 2011-2014
Figure 5.71 Temodar Revenue Forecast ($bn), 2015-2025
Figure 5.72 Temodar: Drivers and Restraints, 2015-2025
Figure 5.73 Faslodex Revenue ($bn), 2011-2014
Figure 5.74 Faslodex Revenue Forecast ($bn), 2015-2025
Figure 5.75 Faslodex: Drivers and Restraints, 2015-2025
Figure 5.76 Abraxane Revenue ($bn), 2011-2014
Figure 5.77 Abraxane: Revenue Forecast ($bn), 2015-2025
Figure 5.78 Abraxane: Drivers and Restraints, 2015-2025
Figure 6.1 Farydak: Revenue Forecast ($bn), 2015-2025
Figure 6.2 Ibrance: Revenue Forecast ($bn), 2015-2025
Figure 6.3 Lenvima: Revenue Forecast ($bn), 2015-2025
Figure 6.4 Opdivo: Revenue Forecast ($bn), 2015-2025
Figure 6.5 Unituxin: Revenue Forecast ($bn), 2015-2025
Figure 6.6 Beleodaq: Revenue Forecast ($bn), 2015-2025
Figure 6.7 Blincyto: Revenue Forecast ($bn), 2015-2025
Figure 6.8 Cyramza: Revenue Forecast ($bn), 2015-2025
Figure 6.9 Imbruvica: Revenue Forecast ($bn), 2015-2025
Figure 6.10 Keytruda: Revenue Forecast ($bn), 2015-2025
Figure 6.11 Lynparza: Revenue Forecast ($bn), 2015-2025
Figure 6.12 Zydelig: Revenue Forecast ($bn), 2015-2025
Figure 6.13 Zykadia: Revenue Forecast ($bn), 2015-2025
Figure 6.14 Tafinlar: Revenue Forecast ($bn), 2015-2025
Figure 6.15 Kadcyla: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Anti-Cancer Drug Market Share (%) by Leading Company, 2013
Figure 7.2 Anti-Cancer Drugs Market Share (%) by Leading Company, 2014
Figure 7.3 Roche’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.4 Novartis’ Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.5 Celgene’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.6 Eli Lilly’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.7 AstraZeneca’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.8 Bristol-Myers Squibb’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.9 Merck’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 7.10 J&J Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
Figure 11.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2014

【レポートのキーワード】

がん治療薬、がん免疫療法、がん化学療法、がん標的治療、がんホルモン治療、企業動向、治療、研究開発、市場予測、抗癌剤

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん治療薬の世界市場:企業動向、治療、研究開発、市場予測(World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆